Dataset from A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed

This study is designed to assess the antiviral activity and safety of a two-drug regimen of
CAB LA + RPV LA compared with maintenance of BIK. BIKTARVY is a registered trademark of
Gilead Sciences.